Whither Radioimmunotherapy: To Be or Not To Be?
Whither Radioimmunotherapy: To Be or Not To Be?
复制标题
DOI：
10.1158/0008-5472.can-16-2523
复制
发表时间：
2017-05-01
期刊：
影响因子：
11.2
通讯作者：
Press OW
中科院分区：
文献类型：
--
作者：
Green DJ;Press OW
用放射性标记的单克隆抗体治疗癌症在临床前实验和在放射敏感性恶性肿瘤，特别是B细胞淋巴瘤中进行的临床试验中产生了令人印象深刻的结果。两种“第一代”直接放射性标记的抗CD 20抗体，131碘-托西莫单抗和90钇-替伊莫单抗在十多年前获得FDA批准，但由于各种医疗、财务和物流障碍，很少使用。采用多步“预靶向”方法的较新技术，特别是那些利用双特异性抗体的技术，极大地增强了放射免疫疗法（RIT）的治疗功效并降低了其毒性。双特异性抗体预靶向的显著改善的治疗指数似乎足以证明人类临床试验的合理性，并重振RIT治疗恶性肿瘤，特别是淋巴瘤的热情。
Therapy of cancer with radiolabeled monoclonal antibodies has produced impressive results in preclinical experiments and in clinical trials conducted in radiosensitive malignancies, particularly B cell lymphomas. Two “first generation”, directly radiolabeled anti-CD20 antibodies, 131Iodine-tositumomab and 90Yttrium-ibritumomab tiuxetan were FDA-approved more than a decade ago, but have been little utilized due to a variety of medical, financial, and logistic obstacles. Newer technologies employing multi-step “pretargeting” methods, particularly those utilizing bispecific antibodies, have greatly enhanced the therapeutic efficacy of radioimmunotherapy (RIT) and diminished its toxicities. The dramatically improved therapeutic index of bispecific antibody pretargeting appears to be sufficiently compelling to justify human clinical trials and reinvigorate enthusiasm for RIT in the treatment of malignancies, particularly lymphomas.